What is the current size and annual growth rate of the aryl hydrocarbon receptor market?
The aryl hydrocarbon receptor market size has grown strongly in recent years. It will grow from $4.64 billion in 2024 to $5.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising awareness of environmental toxins, increasing research in oncology, a rise in autoimmune disease studies, growing interest in targeted therapies, and expanding applications in drug development.
The aryl hydrocarbon receptor market size is expected to see strong growth in the next few years. It will grow to $6.79 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing investment in precision medicine, a rise in demand for immunotherapy, an increasing focus on environmental health, a rise in applications for inflammatory diseases, and increasing advancements in drug discovery. Major trends in the forecast period include advancement in targeted cancer therapies, adoption of precision medicine approaches, advancement in toxicology research, adoption of AI in drug discovery, and advancement in autoimmune disease treatment.
Get Your Free Sample of The Global Aryl Hydrocarbon Receptor Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21106&type=smp
Which major factors have contributed to the expansion of the aryl hydrocarbon receptor market?
The rise in autoimmune diseases and chronic conditions is expected to propel the growth of the aryl hydrocarbon receptor market going forward. Autoimmune diseases and chronic conditions are long-term disorders where the immune system malfunctions or health issues persist. The increase in autoimmune diseases and chronic conditions is rising due to genetics, environment, lifestyle, gut imbalances, and better diagnostics. Aryl hydrocarbon receptor (AHR) agonists can modulate immune responses and inflammation, offering potential therapeutic benefits in autoimmune diseases and chronic conditions by regulating T-cell differentiation and immune cell function. For instance, in July 2023, according to the data from Public Health Scotland, a Scotland-based government agency, in 2022, newly diagnosed patients with multiple sclerosis (MS) increased to 87.2%, up from 85.7%., with 491 new cases reported, bringing the total to 6,359 in 2022. Therefore, the rise in autoimmune diseases and chronic conditions is driving the aryl hydrocarbon receptor (AHR) agonist market.
How is the aryl hydrocarbon receptor market segmented?
The aryl hydrocarbon receptor market covered in this report is segmented –
1) By Type: CB-993113, CDR-914K058, Cinnabarinic Acid, Other Types
2) By Distribution Channel: Direct Sales, Online Platforms, Distributors, Retail Pharmacies, Wholesale Suppliers
3) By Application: Hepatocellular Carcinoma, Multiple Sclerosis, Obesity, Osteoporosis, Other Applications
4) By End-User Industry: Pharmaceuticals, Biotechnology, Agriculture, Environmental Consultancy, Research Institutions
Subsegments:
1) By CB-993113: Preclinical Stage CB-993113, Clinical Trials of CB-993113, Targeted Applications of CB-993113
2) By CDR-914K058: Preclinical Development of CDR-914K058, CDR-914K058 in Immunological Disorders, Targeted Therapeutic Areas for CDR-914K058
3) By Cinnabarinic Acid: Mechanism Of Action Of Cinnabarinic Acid, Cinnabarinic Acid In Inflammatory Conditions, Potential Applications In Neurodegenerative Diseases
4) By Other Types: Synthetic Aryl Hydrocarbon Receptor Agonists, Natural Aryl Hydrocarbon Receptor Ligands, Novel Aryl Hydrocarbon Receptor Modulators
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/aryl-hydrocarbon-receptor-global-market-report
Who are the top competitors in the aryl hydrocarbon receptor market?
Major companies operating in the aryl hydrocarbon receptor market are Bayer AG, Eli Lilly and Company, Organon & Co., Sigma-Aldrich Corporation, Bio-Techne Corporation, Abcam plc, R&D Systems Inc., Dermavant Sciences Inc., Cayman Chemical Company, Enzo Life Sciences Inc., Tocris Bioscience, Ikena Oncology Inc., MedChemExpress LLC, Hercules Pharmaceuticals BV, Active Biotech AB, AnTolRx Inc., Aqilion AB, Azora Therapeutics Australia Pty Ltd, Sol-Gel Technologies Ltd., Actavalon Inc.
Which key trends are expected to influence the aryl hydrocarbon receptor market in the coming years?
Major companies operating in the aryl hydrocarbon receptor market are focusing on developing advanced products, such as topical medication to target specific inflammatory pathways, offering potential treatments for autoimmune diseases like psoriasis, multiple sclerosis, and other chronic inflammatory conditions, while minimizing systemic side effects. Topical medication refers to drugs that are applied directly to the skin or mucous membranes to treat localized conditions or symptoms. For instance, in May 2022, Dermavant Sciences, a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1%. It offers a unique non-steroidal treatment option, providing a novel mechanism of action through its selective aryl hydrocarbon receptor modulation. This cream is designed to be applied once daily, making it a convenient option for patients. It has shown a favorable safety profile with minimal systemic absorption, distinguishing it from traditional therapies.
Which regional trends are influencing the aryl hydrocarbon receptor market, and which area dominates the industry?
North America was the largest region in the aryl hydrocarbon receptor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aryl hydrocarbon receptor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Aryl Hydrocarbon Receptor Market Report 2025 Offer?
The aryl hydrocarbon receptor market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Aryl hydrocarbon receptor refers to a protein that binds environmental pollutants, such as dioxins, and regulates gene expression involved in immune and inflammatory responses. It is used for modulating various biological processes, including the treatment of autoimmune and inflammatory conditions like psoriasis, through selective activation or inhibition.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21106
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
